Compare · BMY vs TAK
BMY vs TAK
Side-by-side comparison of Bristol-Myers Squibb Company (BMY) and Takeda Pharmaceutical Company Limited (TAK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMY and TAK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- BMY is the larger of the two at $116.30B, about 2.2x TAK ($52.09B).
- Over the past year, BMY is up 19.7% and TAK is up 8.9% - BMY leads by 10.9 points.
- TAK has been more active in the news (12 items in the past 4 weeks vs 11 for BMY).
- BMY has more recent analyst coverage (25 ratings vs 6 for TAK).
- Company
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Price
- $56.94-0.76%
- $16.53-0.18%
- Market cap
- $116.30B
- $52.09B
- 1M return
- -4.04%
- -9.33%
- 1Y return
- +19.75%
- +8.89%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 11
- 12
- Recent ratings
- 25
- 6
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc, and Rani Therapeutics LLC; a license and research agreement with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc.; a research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Latest BMY
- EVP, Chief Commercial Officer Lenkowsky Adam converted options into 1,373 shares, disposed of 203 shares and covered exercise/tax liability with 599 shares, increasing direct ownership by 3% to 19,706 units (SEC Form 4)
- Bristol Myers Squibb Launches "Won't Lose" Media Campaign Ahead of FIFA World Cup 2026™
- SEC Form 10-Q filed by Bristol-Myers Squibb Company
- Bristol-Myers Squibb Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Bristol Myers Squibb Reports First Quarter Financial Results for 2026
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
- Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
- Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
- SEC Form DEFA14A filed by Bristol-Myers Squibb Company
Latest TAK
- British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome
- SEC Form 3 filed by new insider Smoter Jennifer Marie
- Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
- President and CEO Weber Christophe Pierre was granted 78,900 units of Ordinary Shares and was granted 165,370 units of American Depositary Shares, decreasing direct ownership by 55% to 418,803 units (SEC Form 4) to cover taxes
- President, R&D Plump Andrew Stewart was granted 212,470 units of American Depositary Shares, increasing direct ownership by 36% to 806,572 units (SEC Form 4)
- Head, Strat. & Port. Dev. Pignagnoli Agosti Marcello was granted 27,740 units of American Depositary Shares, increasing direct ownership by 19% to 172,348 units (SEC Form 4)
- Chief Transformation Officer Duprey Lauren Rusckowski was granted 59,990 units of American Depositary Shares, increasing direct ownership by 36% to 228,503 units (SEC Form 4)
- CEO - Elect Kim Julie So-Young was granted 105,416 units of American Depositary Shares, increasing direct ownership by 32% to 430,145 units (SEC Form 4)
- Chief Data & Tech. Officer Ricci Gabriele was granted 34,994 units of American Depositary Shares, increasing direct ownership by 28% to 159,126 units (SEC Form 4)
- Chief Financial Officer Furuta Milano was granted 7,800 units of Ordinary Shares, increasing direct ownership by 16% to 57,900 units (SEC Form 4) (withholding obligation)